CancerDrs

Breast Cancer clinical trials in Texas

102 actively recruiting breast cancer trials at 49 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Texas:
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
  • UTMB Health Angleton Danbury Campus — Angleton, Texas
  • Houston Methodist San Jacinto Hospital — Baytown, Texas
  • UT MD Anderson - The Woodlands — Conroe, Texas
  • Houston Methodist Cypress Hospital — Cypress, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Texas:
  • Dell Seton Medical Center at The University of Texas — Austin, Texas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
  • Ben Taub General Hospital — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in Texas:
  • UT MD Anderson - The Woodlands — Conroe, Texas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
  • Ben Taub General Hospital — Houston, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
  • UT MD Anderson - West Houston — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Texas:
  • Hendrick Health System — Abilene, Texas
  • Texas Oncology — Austin, Texas
  • Texas Oncology — El Paso, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Joe Arrington Cancer Research and Treatment Center — Lubbock, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…

Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in Texas:
  • Research Site — Austin, Texas
  • Research Site — Dallas, Texas
  • Research Site — Denton, Texas
  • Research Site — Houston, Texas
  • Research Site — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…

Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Texas:
  • Texas Oncology-Northeast Texas — Allen, Texas
  • Texas Oncology - Central South (Balcones Dr) — Austin, Texas
  • Texas Oncology - Central South (James Casey) — Austin, Texas
  • Texas Oncology-Northeast Texas — Denison, Texas
  • Texas Oncology-Northeast Texas — Denton, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…

Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Texas:
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • Mary Crowley Cancer Research — Dallas, Texas
  • DHR Health Oncology Institute — Edinburg, Texas
  • Texas Oncology - Fredericksburg — Fredericksburg, Texas
  • Texas Oncology - Harlingen — Harlingen, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…

Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in Texas:
  • OneR The Center For Cancer And Blood Disorders (Texas Cancer Care) — Arlington, Texas
  • OneR The Center For Cancer And Blood Disorders (Texas Cancer Care) — Burleson, Texas
  • UT Southwestern Medical Center at Redbird — Dallas, Texas
  • University Of Texas Southwestern Medical Center — Dallas, Texas
  • JPS Health Network - Trinity Springs Pavilion — Fort Worth, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Texas:
  • Research Site — Dallas, Texas
  • Research Site — Dallas, Texas
  • Research Site — Dallas, Texas
  • Research Site — El Paso, Texas
  • Research Site — Flower Mound, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Texas:
  • Hendrick Medical Center ( Site 0009) — Abilene, Texas
  • Texas Oncology - DFW ( Site 8009) — Dallas, Texas
  • UT Southwestern ( Site 0092) — Dallas, Texas
  • Texas Oncology - Northeast Texas ( Site 8002) — Flower Mound, Texas
  • JPS Oncology and Infusion Center ( Site 0083) — Fort Worth, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Texas:
  • JPS Health Network — Fort Worth, Texas
  • Community Clinical Trials — Spring, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Texas:
  • Clinical Trial Site — Dallas, Texas
  • Clinical Trial Site — Dallas, Texas
  • Clinical Trial Site — Denton, Texas
  • Clinical Trial Site — El Paso, Texas
  • Clinical Trial Site — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…

Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Texas:
  • Research Site — Houston, Texas
  • Research Site — Houston, Texas
  • Research Site — Houston, Texas
  • Research Site — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Texas:
  • Texas Oncology Central/South — Austin, Texas
  • Texas Oncology DFW — Dallas, Texas
  • University of Texas Southwestern Medical Center — Dallas, Texas
  • Houston Methodist Hospital Cancer Center — Houston, Texas
  • The University of Texas M.D. Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Texas:
  • Texas Oncology - Austin — Austin, Texas
  • Texas Oncology - Dallas Presbyterian Hospital — Dallas, Texas
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • The University of Texas Southwestern Medical Center — Dallas, Texas
  • Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Texas:
  • Texas Oncology - Fort Worth — Fort Worth, Texas
  • U.T. MD Anderson Cancer Center, Investigational Pharmacy Services — Houston, Texas
  • Millennium Research and Clinical Development — Houston, Texas
  • Maryland Oncology Hematology Healing Way - USOR — Irving, Texas
  • Medical Oncology Hematology Consultants — Irving, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Texas:
  • Texas Oncology-Dallas Presbyterian Hospital ( Site 8000) — Dallas, Texas
  • Parkland Health and Hospital System ( Site 0069) — Dallas, Texas
  • UT Southwestern Medical Center ( Site 0050) — Dallas, Texas
  • The Center for Cancer and Blood Disorders ( Site 0041) — Fort Worth, Texas
  • Texas Oncology - San Antonio ( Site 8002) — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Texas:
  • Texas Oncology - Central/South Texas — Austin, Texas
  • Texas Oncology - West Texas — El Paso, Texas
  • Texas Oncology - Northeast Texas — Flower Mound, Texas
  • (USOR) Texas Oncology — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…

Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Texas:
  • Baylor College of Medicine — Houston, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Harris Health System - Smith Clinic — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in Texas:
  • Texas Oncology - DFW ( Site 8003) — Dallas, Texas
  • JPS Health Network ( Site 0067) — Fort Worth, Texas
  • Texas Oncology - Gulf Coast ( Site 8006) — Houston, Texas
  • Oncology Consultants P.A. ( Site 0061) — Houston, Texas
  • Texas Oncology - Central/South Texas ( Site 8005) — McAllen, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …

Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Texas:
  • The Center for Cancer and Blood Disorders - Breast Center — Fort Worth, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • Mays Cancer Center — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.

Sponsor: Hoffmann-La Roche
NCT ID: NCT07413939
Sites in Texas:
  • Texas Oncology Cancer Center — Austin, Texas
  • The Center for Cancer and Blood Disorders - Fort Worth — Fort Worth, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype Evaluation

To compare the outcomes of and responses to 2 different radiation therapy schedules (the standard radiation amount and number of doses versus less radiation and fewer doses) that are being given before having breast cancer surgery (cancer …

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT05774678
Sites in Texas:
  • M D Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Texas:
  • Hendrick Medical Center — Abilene, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • Lyndon Baines Johnson General Hospital — Houston, Texas
  • Houston Methodist Hospital — Houston, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →

Showing 25 of 102 trials with sites in Texas. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12